Track topics on Twitter Track topics that are important to you
Futura Medical PLC’s (LON:FUM) CEO James Barder tells Proactive’s Andrew Scott negotiations over a deal with a partner that would help commercialise their breakthrough erectile dysfunction treatment are at an advanced stage.
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate or carry significant side-effects.
The update came a day after Futura announced interim data which indicated its lead drug can be administered in at least two higher-strength doses.
This has a knock-on positive impact for the imminent phase III clinical trial of MED2002, which is hoped will rubber stamp its huge potential.NEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Erectile dysfunction (ED or impotence) is the inability to get and maintain an erection that is sufficient for satisfactory sexual intercourse, and affects half of all men between the ages of 40 to 70. The causes of ED can be both physical and psycholo...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...